GSK press releases Follow GSK’s Nucala (mepolizumab) approved in China for treatment of adults with chronic rhinosinusitis with nasal polyps This is the third indication for mepolizumab in China for an IL-5 mediated condition https://www.gsk.com/en-gb/media/press-releases/gsk-s-nucala-mepolizumab-approved-in-china-for-treatment-of-adults-with-chronic-rhinosinusitis-with-nasal-polyps/ gsk.com
